Busulfan test dose (DrugBank: Busulfan)
13 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
19 | Lysosomal storage disease | 0 |
20 | Adrenoleukodystrophy | 0 |
28 | Systemic amyloidosis | 0 |
36 | Epidermolysis bullosa | 0 |
49 | Systemic lupus erythematosus | 0 |
51 | Scleroderma | 0 |
60 | Aplastic anemia | 0 |
65 | Primary immunodeficiency | 1 |
164 | Oculocutaneous albinism | 0 |
274 | Osteogenesis Imperfecta | 0 |
284 | Diamond-Blackfan anemia | 0 |
285 | Fanconi anemia | 0 |
326 | Osteopetrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04339777 (ClinicalTrials.gov) | September 22, 2020 | 8/4/2020 | Allogeneic Hematopoietic Stem Cell Transplant for People With Primary Immunodeficiency Diseases | A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immunodeficiency Diseases | Lymphoproliferative Disorders;Autoimmune Lymphoproliferative;Immune System Diseases;Common Variable Immunodeficiency;Primary T-cell Immunodeficiency Disorders | Drug: Busulfan test dose;Drug: Fludarabine;Drug: Busulfan;Drug: Alemtuzumab;Radiation: Total body Irradiation;Procedure: Allogeneic HSCT;Drug: Tacrolimus (Tacro);Drug: Mycophenolate mofetil (MMF);Drug: Cyclophosphamide (Cytoxan) | National Cancer Institute (NCI) | NULL | Recruiting | 4 Years | 69 Years | All | 56 | Phase 2 | United States |